Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.

Rajesh Pandey1, G K Khuller

  • 1Department of Biochemistry, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India.

Tuberculosis (Edinburgh, Scotland)
|June 1, 2005
PubMed
Summary

Nebulized solid lipid particles (SLPs) loaded with tuberculosis drugs offer improved bioavailability and prolonged drug release. This approach significantly reduces treatment frequency for pulmonary tuberculosis, enhancing therapeutic outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional landscapes of dengue patients reveal associations between HERV activity and disease severity.

NAR molecular medicine·2026
Same author

Intracellular microbial shifts during COVID-19 infection and longitudinal recovery revealed by single-cell RNA sequencing.

iScience·2026
Same author

Comparative GWAS using global and Indian Reference Panels reveals non-coding drivers of COVID-19 severity and mortality.

PLoS neglected tropical diseases·2026
Same author

Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential.

PloS one·2026
Same author

Phloretin-induced modulation in gut microbiome, mitigates colonic inflammation and alleviates colitis-associated colorectal cancer in mice.

Computational and structural biotechnology journal·2026
Same author

Functional dynamics between resident transcriptionally active microbes (TAMs) and host genes underlie Dengue severity.

PLoS neglected tropical diseases·2025

Area of Science:

  • Pharmacology
  • Nanotechnology
  • Infectious Diseases

Background:

  • Tuberculosis remains a significant global health challenge, requiring effective and convenient treatment strategies.
  • Conventional antitubercular drug delivery often involves frequent dosing and can lead to toxicity.
  • Developing novel drug delivery systems is crucial for improving patient compliance and treatment efficacy.

Purpose of the Study:

  • To evaluate the chemotherapeutic potential of nebulized solid lipid particles (SLPs) containing rifampicin, isoniazid, and pyrazinamide for treating experimental tuberculosis.
  • To assess the pharmacokinetic profile and therapeutic efficacy of SLP-based antitubercular drugs delivered via nebulization.
  • To investigate the potential of this novel delivery system to reduce dosing frequency and improve drug bioavailability.

Related Experiment Videos

Main Methods:

  • Solid lipid particles (SLPs) were prepared using the emulsion solvent diffusion technique.
  • The prepared SLPs incorporated rifampicin, isoniazid, and pyrazinamide.
  • Pharmacokinetic studies were conducted in guinea pigs following nebulization, assessing drug concentrations in plasma and organs over time.
  • Therapeutic efficacy was evaluated in Mycobacterium tuberculosis-infected guinea pigs, comparing nebulized SLPs with orally administered free drugs.

Main Results:

  • Nebulized SLPs demonstrated a suitable aerodynamic diameter for bronchoalveolar delivery.
  • Therapeutic drug concentrations were sustained in plasma for 5 days and in organs for 7 days post-nebulization, compared to 1-2 days for free drugs.
  • SLP formulation significantly improved mean residence time and drug bioavailability.
  • In infected guinea pigs, 7 doses of nebulized SLPs eradicated tubercle bacilli, whereas 46 daily oral doses were needed for equivalent benefit.
  • No biochemical hepatotoxicity was observed with the SLP formulation.

Conclusions:

  • Nebulization of SLP-based antitubercular drugs is a promising strategy for pulmonary tuberculosis management.
  • This approach enhances drug bioavailability and allows for a substantial reduction in dosing frequency.
  • The findings support the development of SLP-based nebulized therapies for improved tuberculosis treatment outcomes and patient compliance.